# Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

> **NCT02446600** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 579 (actual)

## Conditions studied

- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Transitional Cell Carcinoma
- Fallopian Tube Undifferentiated Carcinoma
- Ovarian Clear Cell Adenocarcinoma
- Ovarian Endometrioid Tumor
- Ovarian Seromucinous Carcinoma
- Ovarian Serous Tumor
- Ovarian Transitional Cell Carcinoma
- Ovarian Undifferentiated Carcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Ovarian Endometrioid Adenocarcinoma
- Recurrent Primary Peritoneal Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Carboplatin
- **DRUG:** Cediranib Maleate
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Echocardiography Test
- **DRUG:** Gemcitabine
- **DRUG:** Gemcitabine Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Multigated Acquisition Scan
- **DRUG:** Olaparib
- **DRUG:** Paclitaxel
- **DRUG:** Pegylated Liposomal Doxorubicin Hydrochloride
- **OTHER:** Pharmacological Study
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT02446600
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-03-28
- **Primary completion:** 2020-02-23
- **Final completion:** 2027-03-04
- **Target enrollment:** 579 (ACTUAL)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02446600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02446600, "Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02446600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*